Related references
Note: Only part of the references are listed.Novel therapies for immune thrombocytopenia
David J. Kuter
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Constantine S. Tam et al.
BLOOD ADVANCES (2022)
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
David J. Kuter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis
Yu-ting Liu et al.
ACTA PHARMACOLOGICA SINICA (2021)
Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)
Tianshu Yu et al.
BLOOD (2021)
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs
Candida Vitale et al.
BLOOD (2021)
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish et al.
JOURNAL OF IMMUNOLOGY (2021)
Emerging Therapies in Immune Thrombocytopenia
Sylvain Audia et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
Philipp von Hundelshausen et al.
CANCERS (2021)
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupinan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study
D. F. Murrell et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Garth E. Ringheim et al.
FRONTIERS IN IMMUNOLOGY (2021)
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
Sining Zhu et al.
FRONTIERS IN ONCOLOGY (2021)
Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time
Rundan Duan et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
The role of Bruton's tyrosine kinase in the immune system and disease
Charlotte McDonald et al.
IMMUNOLOGY (2021)
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Datong Zhang et al.
MOLECULES (2021)
Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
Stefan F. H. Neys et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Stefan F. H. Neys et al.
DRUGS (2021)
CD4+ T cell phenotypes in the pathogenesis of immune thrombocytopenia
Milos Kostic et al.
CELLULAR IMMUNOLOGY (2020)
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Peter Hillmen et al.
FUTURE ONCOLOGY (2020)
An update on the pathophysiology of immune thrombocytopenia
John W. Semple et al.
CURRENT OPINION IN HEMATOLOGY (2020)
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
Daniel Caldeira et al.
PLOS ONE (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A
Sandrine Delignat et al.
HAEMATOLOGICA (2019)
Functional significance of the platelet immune receptors GPVI and CLEC-2
Julie Rayes et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans
Gasim Dobie et al.
BLOOD ADVANCES (2019)
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
Chloe Pek Sang Tang et al.
LEUKEMIA & LYMPHOMA (2018)
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)
Jun Chen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre
Paul J. Hampel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis
Wei Kong et al.
CLINICAL RHEUMATOLOGY (2018)
Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
M. Montillo et al.
BLOOD CANCER JOURNAL (2017)
Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease
Odilia B. J. Corneth et al.
ARTHRITIS & RHEUMATOLOGY (2017)
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia
K. A. Rogers et al.
LEUKEMIA (2016)
Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
Gayathri Natarajan et al.
ONCOIMMUNOLOGY (2016)
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Philip A. Thompson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy
Leslie J. Crofford et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Mechanisms of human autoimmunity
Michael D. Rosenblum et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation
Sheau-Pey Wang et al.
RHEUMATOLOGY (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Bruton's tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system
Gabriela Lopez-Herrera et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Jan A. Burger
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
Katja Fiedler et al.
BLOOD (2011)
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance
Carol Moreno et al.
BLOOD (2010)
Genes on the X chromosome affect development of collagen-induced arthritis in mice
L. JANSSON et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes
Yanjie Lu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2008)
Platelet integrin αIIbβ3:: activation mechanisms
Y.-Q. Ma et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
TEC-family kinases: Regulators of T-helper-cell differentiation
PL Schwartzberg et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Platelet glycoprotein VI: its structure and function
M Moroi et al.
THROMBOSIS RESEARCH (2004)
Tec kinases:: A family with multiple roles in immunity
WC Yang et al.
IMMUNITY (2000)
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features
FR Mauro et al.
BLOOD (2000)
Share Paper
